Sirion SRFR-001 Study

This study is a Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects with Age Related Macular Degeneration.  There is currently no treatment for geographic atrophy other than this and other experimental protocols. 

 

We are currently recruiting for this study men and women ages 50 to 89 years of age with geographic atrophy, macular degeneration, and vision ranging from 20/20 to 20/100.  Subjects will be given  PreserVision Lutein and either Fenretinide or placebo soft gel capsules to take throughout the 24 month study.  Study evaluations will occur at day 1 and then months 1, 3, 6, 12, 18, 24, and 25.  Patients will receive the following testing procedures during the course of the study: eye exams, vital signs, physical examination, laboratory tests, reading rate test, contrast sensitivity test, night vision questions, retinal photography, fluorescein angiography, and optical coherence tomography.

   Retina Center

Minnesota

 

Contact Us

Tel: (612) 871-2292

       (800) 233-8504

Fax: (612) 871-0195

staff@retinadocs.com